Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. **Listing of Claims:**

1. – 47. (Canceled)

48. (Currently Amended) A method for inducing a cellular immune response in a patient against a tumor that expresses carcinoembryonic antigen (CEA), said method comprising:

administering an effective immunostimulatory amount of transfected T cells to a patient; and

subsequently administering at least one cytokine to said patient;

wherein said transfected T cells are produced by obtaining T cells from the patient and transfecting said T cells with an expression vector to obtain said transfected T cells;

wherein said expression vector comprises a DNA molecule encoding either a chimeric immunoglobulin/T cell receptor or a chimeric immunoglobulin/CD3 protein, and wherein said immunoglobulin-encoding portion of said DNA molecule encodes the variable ~~region~~ regions of a Class III anti-CEA antibody, and further wherein the variable regions of the α and β polypeptide chains of said T cell receptor are replaced by said variable regions of the antibody.

49. (Previously Presented) The method of claim 48, wherein the cytokine is selected from the group consisting of interferon-γ and interleukin-2.

50. CANCEL

51. (Previously Presented) The method of claim 49, wherein said transfected T cells are stimulated *ex vivo* to obtain an increased mass of cells.

52. (Currently Amended) A method for inducing a cellular immune response in a patient against a tumor that expresses carcinoembryonic antigen (CEA), said method comprising:

administering an effective immunostimulatory amount of transfected T cells to a patient; and

subsequently administering at least one cytokine to said patient;

wherein said T cells are produced by obtaining T cells from the patient and transfecting said T cells with an expression vector to obtain said transfected T cells; wherein said expression vector comprises a DNA molecule encoding either a chimeric immunoglobulin/T cell receptor or a chimeric immunoglobulin/CD3 protein, and wherein said immunoglobulin-encoding portion of said DNA molecule encodes the variable ~~region~~ regions of an anti-idiotypic antibody that recognizes a Class III anti-CEA antibody, and further wherein the variable regions of the α and β polypeptide chains of said T cell receptor are replaced by said variable regions of the antibody.

53. (Previously Presented) The method of claim 52, wherein the cytokine is selected from the group consisting of interferon-γ and interleukin-2.

54. CANCEL

55. (Previously Presented) The method of claim 52, wherein said transfected T cells are stimulated *ex vivo* to obtain an increased mass of cells.

56. CANCEL

57. CANCEL

58. (Previously Presented) The method of claim 48, wherein the Class III anti-CEA antibody is MN-14 or humanized MN-14.

59. (Previously Presented) The method of claim 52, wherein the anti-idiotype antibody is WI2.